Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr. Yavuz Selim Silay

Dr. Yavuz Selim Silay

CEO
Washington University in St. Louis
New York

Biography

Biography: Dr. Yavuz Selim Silay is the Co-Founder & CEO of MAIN(MaQasid Angel Investors Network) & chairman of Istanbul Consulting Group. MAIN(MaQasid Angel Investor Network) is one the fast growing global angel investment groups . ICG(Istanbul Consulting Group) which was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube Ä°stanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Archem Diagnostics. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcilar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey.Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories

Research Interest

Research Interest: Interaction with FDA. Development of generic and branded regulatory strategic plans for new product development, life cycle management of marketed products. Evaluation of potential products & in-licensing opportunities. Participate in all aspects of clinical development & study management, providing scientific, medical, and logistical direction and support to studies.Clinical development in CNS/Pain Managing Phase 2-4 clinical trials